Quarterly ResultMay 5, 2026, 04:22 PM
Rhythm Pharma Q1 Product Revenue Jumps 59.3% to $60.1M; Net Loss $(55.6M)
AI Summary
Rhythm Pharmaceuticals reported a significant increase in product revenue for the first quarter of 2026, with net product sales jumping 59.3% to $60.1 million. Despite this strong revenue growth, the company's net loss widened to $(55.6) million, up from $(49.5) million in the prior year's quarter. The company maintains a strong liquidity position, with $340.6 million in cash and short-term investments, which management believes is sufficient to fund operations for at least the next 24 months.
Key Highlights
- Product revenue, net, increased 59.3% to $60.1 million for Q1 2026, up from $37.7 million in Q1 2025.
- Total revenues rose 83.8% to $60.1 million in Q1 2026, compared to $32.7 million in Q1 2025.
- Net loss for Q1 2026 was $(55.6) million, an increase from $(49.5) million in Q1 2025.
- Net loss per share attributable to common stockholders was $(0.83) for Q1 2026, compared to $(0.81) for Q1 2025.
- Cash and cash equivalents totaled $62.1 million as of March 31, 2026, up from $54.3 million at December 31, 2025.
- Short-term investments were $278.5 million as of March 31, 2026, down from $334.6 million at December 31, 2025.
- Net cash used in operating activities was $(44.2) million for Q1 2026, compared to $(40.4) million for Q1 2025.
- Company expects existing cash resources of $340.6 million to fund operations for at least the next 24 months.
Price Impact
More from RYTM